Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Onychomycosis Treatment Market

Onychomycosis Treatment Market Trends

Report ID: GMI5089
Published Date: Aug 2021
Report Format: PDF

Download Free Sample

Onychomycosis Treatment Market Trends

Diabetic patients are susceptible to toenail fungus. Much scientific research has been performed to evaluate whether diabetic people experience a greater risk of onychomycosis than those without diabetes. Most of the studies concluded that they do. According to scientific research, approximately one in three people with diabetes are afflicted with onychomycosis. Onychomycosis in diabetic patients is more than a cosmetic nuisance.

The outcome from untreated cases may include an increased risk of other foot disorders and limb amputation. Therefore, effective onychomycosis treatment in diabetic individuals is of paramount importance.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of onychomycosis treatment surpassed USD 4.2 billion in 2020 and will expand at a CAGR of 5.6% between 2021 and 2027.

Distal subungual onychomycosis accounted for 68% of the market share in 2020 and will grow as DSO is the most common type of onychomycosis.

Allylamine will register a growth rate of 5.4% from 2021 to 2027 due to the rising availability and deployment of such drugs.

North America market captured 40% of revenue share in 2020 and will grow owing to the surgical awareness about onychomycosis infection and the availability of numerous treatment alternatives.